Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research progress on the role of lipotoxicity in the development of type 2 diabetes mellitus

( views:20, downloads:35 )

Author:: No author available

Journal Title:: Chinese Journal of Diabetes

Issue:: 1

DOI:: 10.3969/j.issn.1006-6187.2023.01.015

Key Word:: 糖尿病,2型;脂毒性;胰岛β细胞;内质网应激;胰岛素抵抗

Abstract：肥胖相关脂代谢异常与T2DM发生发展密切相关,是DKD、糖尿病心肌病、代谢相关脂肪性肝病等的重要病理因素.脂毒性直接影响胰岛β细胞、糖代谢途径,导致IR,引起糖脂代谢紊乱、氧化应激、内质网应激及炎症反应.本文对脂毒性在T2DM发生发展中作用的研究进展进行综述.

Reference

[1]范明娟,聂玉强,詹琪,等.利拉鲁肽联合锌alpha2糖蛋白对棕榈酸诱导的HepG2细胞凋亡、脂质代谢和炎症因子表达的影响[J].2021,37(22).
[2]项孙敏.SCGN通过调控ChREBP入核抑制ox-LDL诱导的胰岛β细胞焦亡[D].2021.
[3]严媛丽.Ass1在TLR4介导β细胞代谢性炎症损伤中的作用[D].2021.
[4]傅爱,徐甜甜,杨贞,等.阿魏酸抑制p38 MAPK保护棕榈酸诱导的肝细胞脂毒性[J].2021,(2).
[5]吴丽.促泌素在ox-LDL诱导胰岛β细胞内质网应激中的调控作用及机制[D].2020.
[6]郑翔宇,付宗强,张艳敏,等.下调lncRNA NONRATT021972调控TLR4对糖脂毒性诱导的胰岛β细胞炎症反应[J].2021,34(11).
[7]李晨,闪雪纯,傅继华.脂毒性诱导的非酒精性脂肪性肝炎的研究进展[J].2019,(9).
[8]田雪,邵明燕,马林,等.心血管疾病中脂毒性的机制研究及中医药防治进展[J].2021,(13).
[9]石洁.刺槐素对游离脂肪酸诱导的胰岛β细胞损伤的保护机制研究[D].2020.
[10]赵芳卿,杨雯雯,殷玉杰,等.丹酚酸A激活AMPK及SIRT1减轻棕榈酸诱导的肝细胞脂毒性[J].2021,(3).
[11]李卓.AMPK在萝卜硫素保护糖尿病肾病中的作用和机制研究[D].2021.
[12]施岚尔.基于自噬调控研究降糖三黄片对胰岛β细胞的保护作用及其机制[D].2021.
[13]杨德森.基于线粒体自噬的薯蓣皂苷元改善T2DM脂代谢紊乱所致睾丸损伤的机理研究[D].2021.
[14]《中国老年型糖尿病防治临床指南》编写组.中国老年2型糖尿病防治临床指南（2022年版）[J].2022,30(1).
[15]郝一聪,李强,于萍.脂毒性对胰岛素抵抗及胰岛β细胞功能的影响研究进展[J].2021,(8).
[16]张雁凌,席建军,曹中朝.血清游离脂肪酸与心血管疾病相关性研究进展[J].2021,26(6).
[17]杨茜,邹大进.肥胖与2型糖尿病的共同起源：能量过剩引发肝脏胰岛素抵抗[J].2016,(2).
[18]王婷婷.安石榴苷改善高脂诱导胰岛细胞损伤的机制研究[D].2021.
[19]Tyrrell, Jannifer B.,Hafida, Samar,Stemmer, Paul,etc.Lead (Pb) exposure promotes diabetes in obese rodents[J].2017,39.
[20]Piotr Zabielski,Jarosław Daniluk,Hady Razak Hady,etc.The effect of high‐fat diet and inhibition of ceramide production on insulin action in liver[J].2019,234(2).
[21]Roden Michael,Shulman Gerald I..The integrative biology of type 2 diabetes[J].2019,576(7785).
[22]Vieira-Lara Marcel A.,Dommerholt Marleen B.,Zhang Wenxuan,etc.Age-related susceptibility to insulin resistance arises from a combination of CPT1B decline and lipid overload[J].2021,19(1).
[23]António Bovolini,Juliana Garcia,Maria Amparo Andrade,etc.Metabolic Syndrome Pathophysiology and Predisposing Factors[J].2021,42(3).
[24]Mahfouz, Rana,Khoury, Rhéa,Blachnio-Zabielska, Agnieszka,etc.Characterising the Inhibitory Actions of Ceramide upon Insulin Signaling in Different Skeletal Muscle Cell Models: A Mechanistic Insight.[J].2014,9(7).
[25]徐娇雅,蒋雨薇,杨丽丽,等.降脂颗粒调控UCP2和JNK/c-Jun介导的NLRP3炎症小体活化减轻非酒精性脂肪性肝炎小鼠脂毒性肝损伤[J].2021,(2).
[26]林心君,刘佳绣,陈勇,等.基于GCGR/PKA通路探讨石斛合剂抑制糖尿病大鼠糖异生的机制[J].2022,33(5).
[27]Petersen, Max C.,Vatner, Daniel F.,Shulman, Gerald I..Regulation of hepatic glucose metabolism in health and disease[J].2017,13(10).
[28]Ishii, Megumi,Maeda, Ayumi,Tani, Shuji,etc.Palmitate induces insulin resistance in human HepG2 hepatocytes by enhancing ubiquitination and proteasomal degradation of key insulin signaling molecules[J].2015,566.
[29]Hong, Zhang,Zhijuan, Ge,Sunyinyan, Tang,etc.Erythropoietin ameliorates PA-induced insulin resistance through the IRS/AKT/FOXO1 and GSK-3β signaling pathway, and inhibits the inflammatory response in HepG2 cells.[J].2017,16(2).
[30]Ayse Basak Engin.What Is Lipotoxicity?[J].2017,960.
[31]Suryaprakash,Raichur,Bodo,Brunner,Maximilian,Bielohuby,etc.The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.[J].2019,21.
[32]Paul Angulo,David E. Kleiner,Sanne Dam-Larsen,etc.Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease[J].2015,149(2).
[33]Ruegsegger, Gregory N.,Creo, Ana L.,Cortes, Tiffany M.,etc.Altered mitochondrial function in insulin-deficient and insulin-resistant states[J].2018,128(9).
[34]T.Y. He,L. Qing,F. Yan,etc.Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease[J].2018,81.
[35]Ji-Hyun,Kim,Hyun A,Sim,Dae Young,Jung,etc.Poria cocus Wolf Extract Ameliorates Hepatic Steatosis through Regulation of Lipid Metabolism, Inhibition of ER Stress, and Activation of Autophagy via AMPK Activation.[J].2019,20(19).
[36]Chaurasia, Bhagirath,Summers, Scott A..Ceramides in Metabolism: Key Lipotoxic Players[J].2021,83.
[37]Kevin P, Foley,Amira, Klip.Dynamic GLUT4 sorting through a syntaxin-6 compartment in muscle cells is derailed by insulin resistance-causing ceramide.[J].2014,3.
[38]朱敏,王洪,沈敏,等.高频超声在胰岛素注射皮下脂肪增生临床筛查中的应用[J].2021,(8).
[39]Moien Abdul Basith,Khan,Muhammad Jawad,Hashim,Jeffrey Kwan,King,etc.Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends.[J].2020,10(1).
[40]Giovanni Musso,Maurizio Cassader,Elena Paschetta,etc.Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis[J].2018,155(2).
[41]Sung Sup,Park,Young-Kyo,Seo.Excess Accumulation of Lipid Impairs Insulin Sensitivity in Skeletal Muscle.[J].2020,21(6).
[42]Mingxia Zhao,Lihong Shen,Zijun Ouyang,etc.Loss of hnRNP A1 in murine skeletal muscle exacerbates high-fat diet-induced onset of insulin resistance and hepatic steatosis[J].2020,12(4).
[43]李琳.四妙勇安汤抗糖尿病心肌病的效应成分及分子机制研究[D].2021.
[44]Esther,Phielix,Paul,Begovatz,Sofiya,Gancheva,etc.Athletes feature greater rates of muscle glucose transport and glycogen synthesis during lipid infusion.[J].2019,4(21).
[45]Lyu, Kun,Zhang, Ye,Zhang, Dongyan,etc.A Membrane-Bound Diacylglycerol Species Induces PKC epsilon-Mediated Hepatic Insulin Resistance[J].2020,32(4).
[46]Pereira,S.,Park,E.,Mori,Y.,etc.FFA-induced hepatic insulin resistance in vivo is mediated by PKCδ, NADPH oxidase, and oxidative stress[J].2014,307(1 Pt.1).
[47]Lebeaupin, Cynthia,Vallee, Deborah,Hetz, Claudio,etc.Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease[J].2018,69(4).
[48]Yaribeygi, Habib,Katsiki, Niki,Butler, Alexandra E.,etc.Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys[J].2019,24(1).
[49]Rossi, Mario,Zhu, Lu,McMillin, Sara M.,etc.Hepatic G(i) signaling regulates whole-body glucose homeostasis[J].2018,128(2).